Monographie - Propofol - Stabilis 4.0

Utolsó frissítés :
19/11/2024

Propofol

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Abbofol	Lengyelország
Anesia	Németország
Diprivan	Amerikai Egyesült Államok, Argentína, Ausztrália, Ausztria, Chile, Colombia, Dánia, Egyiptom, Finnország, Franciaország, Hollandia, Irán, Írország, Kanada, Lengyelország, Luxemburg, Magyarország, Marokkó, Mexikó, Nagy-Britannia, Olaszország, Peru, Portugália, Spanyolország, Svédország, Szaúd-Arábiában, Törökország, Tunézia, új-Zéland, Venezuela
Diprofol	Írország
Disoprivan	Németország, Svájc
Fresofol	Argentína, Colombia, India, Malaysia, Mexikó, új-Zéland
Gobbifol	Argentína
Indufol	Colombia
Plofed	Lengyelország
Pofol	Törökország
Propolipid	Németország, Norvégia, Svédország
Propovan	Argentína
Recofol	Egyesült Arab Emírségek, Egyiptom, Finnország, Irán, Spanyolország, Szaúd-Arábiában
Troypofol	Colombia, Egyesült Arab Emírségek

Irodalom : Propofol

	Type	publikáció
125	Napló	Chernin EL, Stewart JT, Smiler B. Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4°C. Am J Health-Syst Pharm 1996 ; 53: 1576-1579.
126	Napló	Prankerd RJ, Jones RD. Physicochemical compatibility of propofol with thiopental sodium. Am J Health-Syst Pharm 1996 ; 53: 2606-2610.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
309	Napló	Bhatt-Mehta V, Paglia RE, Rosen DA. Stability of propofol with parenteral nutrient solutions during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 192-196.
319	Napló	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
347	Napló	Bailey LC, Tang KT, Rogozinski BA. Effect of syringe filter and IV administration set on delivery of propofol emulsion. Am J Hosp Pharm 1991 ; 48: 2627-2630.
660	Napló	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
794	Napló	Lilley EMM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia 1996 ; 51: 815-818.
813	Napló	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
815	Napló	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
919	Napló	Lazar ER, Jolly DT, Tam YK, Hrazdil J, Tawfik SR, Clanachan AS. Propofol and thiopental in a 1:1 volume mixture is chemically stable. Anesth Analg 1998 ; 86: 422-426.
1508	Napló	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1672	Napló	Lamontagne C, Brouillette D, Hardy JF. Incompatibility of propofol emulsion with anesthesic drugs. Anesthesiology 1998 ; 89: 1609.
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1759	Napló	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Napló	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1860	Napló	Sautou-Miranda V, Levadoux E, Groueix MT, Chopineau J. Compatibility of propofol diluted in 5% glucose with glass and plastics (polypropylene, molyvinylchloride) containers. Int J Pharm 1996 ; 130: 251-255.
1861	Napló	Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J. Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture. Int J Pharm 1996 ; 127: 255-259.
1863	Napló	Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA. Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport. Journal of clinical anesthesia 1996 ; 8: 329-336.
2053	Napló	Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofol-lidocaine mixture. Anesth Analg 2003 ; 97: 1646-1651.
2078	Napló	Loff S, Kabs F, Witt K, Sartoris J, Mandl B, Niessen KH, Waag KL. Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers. J Ped Surg 2000 ; 35: 1775-1781.
2141	Napló	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Napló	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Napló	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2312	Napló	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
2325	Napló	Nemec K, Germ E, Schulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie 2009 ; 64, 2: 94-97.
2329	Napló	Donnely R.F, Willman E, Andolfatto G. Stability of Ketamine-Propofol mixtures for procedural sedation and analgesia in the emergency department. Can J Hosp Pharm 2008 ; 61, 6: 426-430.
3176	poszter	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3249	Napló	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Napló	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3294	Napló	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3332	Laboratórium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Napló	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3502	Laboratórium	Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012
3519	Laboratórium	Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics Glaxo Smith Kline 2011
3601	Laboratórium	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3659	Laboratórium	Propofol (Diprivan®) - Résumé des caractéristiques du produit AstraZeneca 2016
3781	Napló	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3828	poszter	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poszter	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratórium	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
4011	Napló	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4055	Napló	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4080	Napló	Zbytovska J, Gallusova J, Vidlarova L, Prochazkova K, Simek J, Stepanek F. Physical Compatibility of Propofol-Sufentanil Mixtures. Anaesthesia 2017 ;124,3:776-781
4145	Napló	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4157	Napló	Izgi M, Basara B, Muderrisoglu A, Yilbas A.A, Uluer M.S, Celebioglu B. Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia. Pediatric Anesthesia 2018
4331	Napló	Nilsson N, Nezvalova-Henriksen K, Tho I. Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride. Pharmaceutical Technology in Hospital Pharmacy 2019
4433	Napló	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Napló	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4435	Napló	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470	Napló	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4501	Napló	Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A. The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion. BMC Anesthesiology 2020 ;20:283.
4524	poszter	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Napló	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4569	Napló	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4603	Napló	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4801	Napló	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales